MedTrace Logo

Trial of Exercise to Prevent HypeRtension in Young Adults

NCT02723552 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2021-02-02

No results posted yet for this study

Summary

TEPHRA investigates the effect of exercise on blood pressure and other cardiovascular factors in young adults with different birth histories. TEPHRA will recruit 200 participants from 18-35 years old with elevated blood pressure (100 participants pre-term born and 100 full-term born). Half of the participants from each birth group will be randomised into a 16 week supervised aerobic exercise intervention trial and the other half will be controls.

Participants will complete 3 main study visits:

* Visit 1: Baseline visit conducted at beginning of study
* Visit 2: 16 weeks into study (upon completion of structured exercise intervention for the exercise group)
* Visit 3: End of study (52 weeks) Each visit will repeat the same set of cardiovascular measures including CPET, echo, blood pressure, vascular stiffness, and other measures.

50 participants from each group will complete an MRI sub-study of the heart, brain, and liver.

Conditions

Interventions

BEHAVIORAL

Aerobic Exercise

40 minute aerobic exercise sessions 3x/week.

Sponsors & Collaborators

  • Wellcome Trust

    collaborator OTHER

  • Oxford Brookes University

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Paul M Leeson, Phd, FRCP · University of Oxford, Division of Cardiovascular Medicine, Cardiovascular Clinical Research Facility

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-23
Primary Completion
2019-03-29
Completion
2019-11-26

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02723552 on ClinicalTrials.gov